Trial Profile
A Phase I Study of Tagraxofusp With or Without Chemotherapy in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 23 Feb 2024
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Cytarabine (Primary) ; Cytarabine (Primary) ; Dexamethasone (Primary) ; Fludarabine (Primary) ; Hydrocortisone (Primary) ; Methotrexate (Primary) ; Tagraxofusp (Primary) ; Vincristine (Primary)
- Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia; Blastic plasmacytoid dendritic cell neoplasm; Hodgkin's disease; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 13 Dec 2022 Trial design presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 14 Nov 2022 Planned End Date changed from 1 Nov 2027 to 11 Nov 2027.
- 14 Nov 2022 Planned primary completion date changed from 1 Nov 2025 to 11 Nov 2025.